Interplays Between Therapeutic Radiopharmaceuticals and Tumor Microenvironment
Advanced Healthcare Materials · 2026-11-01
DOI: 10.1002/adhm.71869 ↗At a glance
Übersichtsarbeit in Advanced Healthcare Materials, published online on 2026-11-01. Written by Yue Zhang and 9 co-authors. Institution: National Platform for Medical Engineering & Education Integration (NMEE), Zhongda Hospital, Southeast University, Nanjing, China. 246 references. Funded by: National Natural Science Foundation of China, Research Personnel Cultivation Program of Zhongda Hospital Southeast University.
Abstract (original language)
Radiopharmaceuticals have progressed from diagnostic agents toward theranostic. With the accelerating development of therapeutic radiopharmaceuticals, radiopharmaceutical therapy (RPT) is being increasingly implemented in clinical practice in oncology. However, current therapeutic radiopharmaceuticals often contribute to tumor stabilization rather than complete remission. A major determinant of this limited clinical response is the tumor microenvironment (TME), which critically influences the delivery, penetration, and retention of radiopharmaceuticals. Meanwhile, the radiopharmaceuticals can modulate multiple components of the TME, thereby contributing to antitumor effects. These interactions provide opportunities for advancing radiopharmaceuticals to enhance RPT efficacy. In this review, the bidirectional relationship between therapeutic radiopharmaceuticals and TME in solid malignancies is comprehensively discussed. First, common therapeutic strategies that modulate TME are outlined. The impact of the TME on radiopharmaceutical efficacies and how radiopharmaceuticals reshape the TME are then highlighted. In addition to elucidating the bidirectional interplay between RPT and the TME, we examine two fundamental clinical barriers that constrain RPT efficacy: dosimetric limitations and systemic immune collateral damage. Finally, critical challenges and potential strategies to enhance next‐generation therapeutic radiopharmaceuticals in solid malignancies are inspected.
Subjects
Author keywords
Authors and institutions
- National Platform for Medical Engineering & Education Integration (NMEE), Zhongda Hospital, Southeast University, Nanjing, China.
- Department of Radiology, School of Medicine, Southeast University, Nanjing, China.
- School of Chemistry and Chemical Engineering, Southeast University, Nanjing, China.
- Institute of Functional Nano and Soft Materials (FUNSOM), Jiangsu Key Laboratory for Carbon-Based Functional Materials and Devices, Soochow University, Suzhou, China.
ORCID profiles: Yue Zhang, Xudong Xie, Zhengjian Qi, Guanghai Fei, Zhuang Liu, Yicheng Ni
Funding
- National Natural Science Foundation of China
- Research Personnel Cultivation Program of Zhongda Hospital Southeast University
Cite
APA
Zhang, Y., Zhang, Y., Zhao, Y., Ma, J., Xie, X., Qi, Z., Li, Y., Fei, G., Liu, Z., & Ni, Y. (2026). Interplays Between Therapeutic Radiopharmaceuticals and Tumor Microenvironment. Advanced Healthcare Materials. https://doi.org/10.1002/adhm.71869
Vancouver
Zhang Y, Zhang Y, Zhao Y, Ma J, Xie X, Qi Z, et al. Interplays Between Therapeutic Radiopharmaceuticals and Tumor Microenvironment. Advanced Healthcare Materials. 2026. doi:10.1002/adhm.71869
BibTeX
@article{Zhang2026,
author = {Zhang, Yue and Zhang, Ying and Zhao, Yaqi and Ma, Jingya and Xie, Xudong and Qi, Zhengjian and Li, Yue and Fei, Guanghai and Liu, Zhuang and Ni, Yicheng},
title = {Interplays Between Therapeutic Radiopharmaceuticals and Tumor Microenvironment},
journal = {Advanced Healthcare Materials},
year = {2026},
doi = {10.1002/adhm.71869}
}
EUVIMED